

CITATION REPORT

List of articles citing

Royal College of Ophthalmologists guidelines: ocular toxicity and hydroxychloroquine

DOI: 10.1038/eye.1998.236
Eye, 1998, 12 (Pt 6), 907-9.

Source: <https://exaly.com/paper-pdf/29495980/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
40	Management of patients undergoing hydroxychloroquine (Plaquenil) therapy. <i>Australasian journal of optometry, The</i> , 2000 , 83, 32-36	2.7	8
39	Antimalarial therapy: a panacea for mild lupus?. <i>Lupus</i> , 2001 , 10, 148-51	2.6	26
38	Avaliaço da toxicidade ocular por derivados da 4-aminoquinolona. <i>Arquivos Brasileiros De Oftalmologia</i> , 2002 , 65, 645-649	1.1	2
37	The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. <i>Ophthalmology</i> , 2003 , 110, 1321-6	7.3	195
36	Detecting chloroquine retinopathy: electro-oculogram versus colour vision. <i>British Journal of Ophthalmology</i> , 2003 , 87, 902-8	5.5	34
35	Are evidence-based guidelines being followed for the monitoring of ocular toxicity of hydroxychloroquine? A nationwide survey of practice amongst consultant rheumatologists and implications for clinical governance. <i>British Journal of Rheumatology</i> , 2004 , 43, 346-8		13
34	Adherence to guidelines for the monitoring of antimalarial-related retinal toxicity. <i>British Journal of Rheumatology</i> , 2004 , 43, 1058-9; author reply 1059		2
33	The multifocal pattern electroretinogram in chloroquine retinopathy. <i>Ophthalmic Research</i> , 2004 , 36, 106-13	2.9	8
32	Are evidence-based guidelines being followed for the monitoring of ocular toxicity of hydroxychloroquine? A nationwide survey of practice amongst consultant rheumatologists and implications for clinical governance. Comment on the article by Samanta et al. <i>British Journal of Rheumatology</i> , 2004 , 43, 1057-9; author reply 1059		4
31	Management of "refractory" skin disease in patients with lupus erythematosus. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005 , 19, 767-84	5.3	21
30	Ocular toxicity due to chloroquine and hydroxychloroquine: electrophysiological and visual function correlates. <i>Documenta Ophthalmologica</i> , 2005 , 110, 111-20	2.2	48
29	Threshold Amsler grid as a screening tool for asymptomatic patients on hydroxychloroquine therapy. <i>British Journal of Ophthalmology</i> , 2005 , 89, 569-74	5.5	18
28	Multifocal electroretinographic changes in patients receiving hydroxychloroquine therapy. <i>American Journal of Ophthalmology</i> , 2005 , 140, 794-807	4.9	86
27	Ojo y piel. <i>EMC - Dermatología</i> , 2006 , 40, 1-38	0.1	
26	Ocular manifestations of systemic lupus erythematosus: a clinical review. <i>Lupus</i> , 2006 , 15, 3-12	2.6	63
25	Il et peau. <i>EMC - Dermatologie</i> , 2006 , 1, 1-37		
24	Cutaneous lupus erythematosus: a personal approach to management. <i>Australasian Journal of Dermatology</i> , 2006 , 47, 13-27	1.3	55

23	Abnormalities on the multifocal electroretinogram may precede clinical signs of hydroxychloroquine retino-toxicity. <i>Eye</i> , 2006 , 20, 129-32	4.4	15
22	Visual field and multifocal electroretinography and their correlations in patients on hydroxychloroquine therapy. <i>Documenta Ophthalmologica</i> , 2006 , 112, 177-87	2.2	44
21	Early paracentral visual field loss in patients taking hydroxychloroquine. <i>JAMA Ophthalmology</i> , 2006 , 124, 1729-33		42
20	Fundus autofluorescence and mfERG for early detection of retinal alterations in patients using chloroquine/hydroxychloroquine. <i>Investigative Ophthalmology and Visual Science</i> , 2006 , 47, 3531-8		110
19	[Ocular toxicity due to 4-aminoquinoline derivatives]. <i>Arquivos Brasileiros De Oftalmologia</i> , 2007 , 70, 1046-51	1.1	8
18	Prevalence and predictors of ocular manifestations of RA: is there a need for routine screening?. <i>Musculoskeletal Care</i> , 2007 , 5, 102-17	1.6	11
17	The Connective Tissue Diseases 2010 , 1-138		9
16	Macular sensitivity changes for detection of chloroquine toxicity in asymptomatic patient. <i>International Ophthalmology</i> , 2010 , 30, 195-7	2.2	8
15	Impact of the revised american academy of ophthalmology guidelines regarding hydroxychloroquine screening on actual practice. <i>American Journal of Ophthalmology</i> , 2013 , 155, 418-428	4.9	53
14	Hydroxychloroquine and Chloroquine Retinopathy. 2014 ,		25
13	The Prevalence of Hydroxychloroquine Retinopathy and Toxic Dosing, and the Role of the Ophthalmologist in Reducing Both. <i>American Journal of Ophthalmology</i> , 2016 , 166, ix-xi	4.9	18
12	AIMING FOR THE BULL'S EYE: The Cost-Utility of Screening for Hydroxychloroquine Retinopathy. <i>Retina</i> , 2016 , 36, 1958-63	3.6	1
11	Longitudinal Retinal Changes Induced by Hydroxychloroquine in Eyes without Retinal Toxicity. <i>Ophthalmic Research</i> , 2021 , 64, 290-296	2.9	1
10	Two years' experience of screening for hydroxychloroquine retinopathy. <i>Eye</i> , 2021 , 35, 1171-1177	4.4	2
9	The Skin and the Eyes. 1-37		2
8	Hauterkrankungen. 2003 , 1385-1425		
7	Chorioretinal Toxicities. 2010 , 851-880		
6	Screening for Hydroxychloroquine and Chloroquine Retinopathy. 2014 , 227-245		

- 5 Epidemiology of Hydroxychloroquine and Chloroquine Retinopathy. **2014**, 95-106
- 4 Autoimmunerkrankungen. **2005**, 1431-1436
- 3 Rheumatoid arthritis. *Clinical Evidence*, **2007**, 2007, 1
- 2 Toxicidade ocular por cloroquina. *Revista Paulista De Reumatologia*, **2014**, 39-42 0.1
- 1 Clinical aspects of cutaneous lupus erythematosus. 9, 0